SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
SAB Biotherapeutics, Inc. (SABS) is a Biotechnology company based in US with a market capitalization of $34.8M. Free cash flow was negative at -$45.7M. This page tracks SABS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 63 employees · IPO Feb 9, 2021
Valuation
Valuation & price
$3.70as of May 17, 2026· -19.4% vs 52w high
17.1
P/E ratio
Latest-FY diluted EPS
0.23
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$34.8M
Market cap
—
Revenue growth (YoY)
-262.4%
Gross margin
-$45.7M
Free cash flow (USD)
-$90.6M
Net debt
Net cash position
108.5%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is SAB Biotherapeutics, Inc.'s market cap?
SAB Biotherapeutics, Inc. (SABS) has a market capitalization of $34.8M.
What is SABS's P/E ratio?
SABS trades at a price-to-earnings ratio of 17.1, based on its latest fiscal-year diluted earnings per share and the most recent cached price.
What is SABS's price-to-book (P/B) ratio?
SABS trades at 0.23 times book value per share.
Are insiders buying SABS stock?
SEC Form 4 filings show no open-market insider buys at SAB Biotherapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.